Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ëÀå¾ÏȯÀÚ¿¡¼­ Capecitabine (Xeloda?) ´Üµ¶¿ä¹ý¿¡ ÀÇÇÑ ÁõÈıº Hand-foot Syndrome Following Capecitabine (Xeloda¢ç) Monotherapy for Colorectal Cancer

´ëÇÑ´ëÀåÇ×¹®ÇÐȸÁö 2009³â 25±Ç 4È£ p.227 ~ 233
¹Ú¼øµµ, À̱濬, ¹Ú¼±Áø, ÀÌ»ó¸ñ, À̼®È¯,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¼øµµ ( Park Soon-Do ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

À̱濬 ( Lee Kil-Yeon ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹Ú¼±Áø ( Park Sun-Jin ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÀÌ»ó¸ñ ( Lee Sang-Mok ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À̼®È¯ ( Lee Suk-Hwan ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Purpose: Capecitabine (Xeloda¢ç), which is a systemic prodrug of 5-fluorouracil, can be used in oral formulation for treatment of advanced colorectal cancer as a 1st line or an alternative modality to I.V. 5-fluorouracil-based chemotherapy. One of the most common side effects of this drug is hand-foot syndrome (HFS), palmar-plantar erythrodysesthesia syndrome. We planned this study to clarify the incidence and the clinical course of severe hand-foot syndrome (WHO classification, grade 3 or 4) following capecitabine monotherapy for adjuvant treatment of colorectal cancer.

Methods: From August 2006 to August 2008, 45 colorectal cancer patients were treated with capecitabine, 1,250 mg/m2, orally administered twice daily for 2 wk, followed by 1 wk of rest, given as 3-wk cycles. Seven of them discontinued the drug within 3rd cycle due to poor performance status, gastrointestinal troubles, or other causes. We retrospectively analyzed the remaining 38 patients¡¯ medical records and defined the incidence and the clinical course of HFS.


Results: Of the 38 patients, 17 (44.7%) suffered severe HFS after capecitabine monotherapy. Of those 17, 5 (29.4%) had severe symptoms after the 1st chemotherapy cycle, and 14 patients (82.4%) had severe symptoms within the 4th cycle. Three of the 14 female and 14 of the 24 male patients complained of severe HFS, showing a statistical male predominance (P=0.043). Eventually, we had to decrease capecitabine to 75% of the daily dose in 12 patients and to 50% in one patient, and to discontinue its use in 4 patients.


Conslusion: Capecitabine monotherapy very frequently provokes severe HFS, especially in the early cycles of chemotherapy and in males.

Å°¿öµå

¼öÁ·ÁõÈıº;´ëÀå¾Ï
Hand-foot syndrome;Palmar-plantar erythrodysesthesia syndrome

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS